To kill a tumor cell: the potential of proapoptotic receptor agonists

被引：265

作者：

Ashkenazi, Avi ^{[1
]}

Herbst, Roy S. ^{[2
,3
]}

机构：

[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 06期

关键词：

D O I：

10.1172/JCI34359

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for potential therapeutic intervention. There is currently heightened interest in the extrinsic apoptosis pathway, with several proapoptotic receptor agonists (PARAs) in development. The PARAs include the ligand recombinant human Apo2L/TRAIL and agonistic mAbs. Mechanistic and preclinical data with Apo2L/TRAIL indicate exciting opportunities for synergy with conventional therapies and for combining PARAs with other molecularly targeted agents. Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy.

引用

页码：1979 / 1990

页数：12

共 130 条

[81]

Nimmanapalli R, 2001, CANCER RES, V61, P759

[82] Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia [J].

O'Brien, Susan ;

Moore, Joseph O. ;

Boyd, Thomas E. ;

Larratt, Loree M. ;

Skotnicki, Aleksander ;

Koziner, Benjamin ;

Chanan-Khan, Asher A. ;

Seymour, John F. ;

Bociek, R. Gregory ;

Pavletic, Steve ;

Rai, Kanti R. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) :1114-1120

[83]

Odoux C, 2004, VITAM HORM, V67, P385

[84] An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J].

Oltersdorf, T ;

Elmore, SW ;

Shoemaker, AR ;

Armstrong, RC ;

Augeri, DJ ;

Belli, BA ;

Bruncko, M ;

Deckwerth, TL ;

Dinges, J ;

Hajduk, PJ ;

Joseph, MK ;

Kitada, S ;

Korsmeyer, SJ ;

Kunzer, AR ;

Letai, A ;

Li, C ;

Mitten, MJ ;

Nettesheim, DG ;

Ng, S ;

Nimmer, PM ;

O'Connor, JM ;

Oleksijew, A ;

Petros, AM ;

Reed, JC ;

Shen, W ;

Tahir, SK ;

Thompson, CB ;

Tomaselli, KJ ;

Wang, BL ;

Wendt, MD ;

Zhang, HC ;

Fesik, SW ;

Rosenberg, SH .

NATURE, 2005, 435 (7042) :677-681

[85] Defining characteristics of Types I and II apoptotic cells in response to TRAIL [J].

Özören, N ;

El-Deiry, WS .

NEOPLASIA, 2002, 4 (06) :551-557

[86]

PATNAIK A, 2006, P AN M AM SOC CLIN, V24, P3012

[87]

Petak I, 2000, CLIN CANCER RES, V6, P4119

[88] Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks [J].

Pommier, Y ;

Sordet, O ;

Antony, S ;

Hayward, RL ;

Kohn, KW .

ONCOGENE, 2004, 23 (16) :2934-2949

[89] Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL [J].

Ravi, R ;

Jain, AJ ;

Schulick, RD ;

Pham, V ;

Prouser, TS ;

Allen, H ;

Mayer, EG ;

Yu, H ;

Pardoll, DM ;

Ashkenazi, A ;

Bedi, A .

CANCER RESEARCH, 2004, 64 (24) :9105-9114

[90] Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor [J].

Ray, S ;

Bucur, O ;

Almasan, A .

APOPTOSIS, 2005, 10 (06) :1411-1418

← 4 5 6 7 8 9 10 11 12 13 →